TICKERNERD
Menu
CELCCELCHealthcare · Biotechnology

CELC Stock Forecast: Celcuity, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$88
+1.55% on the day

The 12 Wall Street analysts covering Celcuity, Inc. hold a median 12-month price target of $165 — +88.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$4.2B
Ticker Nerd rank
28 / 100
Median analyst target
$165
Analysts covering
12
Total return, dividends reinvested
1W
+6.6%
1M
−18.7%
YTD
−12.1%
1Y
+119.8%
From 52W high
−39.5%
From 52W low
+104.8%
$43
$145
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CELC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Celcuity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
28 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
92
Momentum
80
Quality
46
Volatility
42
Accruals
38
Revisions
32
Growth
29
Size
26
Issuance
6

Value (92): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own Celcuity, Inc. — and when they’d sell — is the membership.

Wall Street

CELC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CELC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200Oct 25Jan 26Apr 26Jul 26CELCHigh $178Median $165Low $148

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says12 analysts
12 Buy0 Hold0 Sell
Low $148Median $165High $178

The green dot is the last close — the median target sits +88.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
15 July 2026CitizensMaintainsMarket Outperform$160 → $177
15 July 2026HC Wainwright & Co.MaintainsBuy$145 → $155
3 June 2026Craig-HallumMaintainsBuy$189 → $171
3 June 2026Craig-HallumMaintainsBuy—
3 June 2026HC Wainwright & Co.MaintainsBuy$185 → $145
3 June 2026HC Wainwright & Co.MaintainsBuy—
3 June 2026Wells FargoMaintainsOverweight—
3 June 2026Wells FargoMaintainsOverweight$183 → $166
18 May 2026HC Wainwright & Co.MaintainsBuy—
15 May 2026NeedhamReiteratesBuy—
15 May 2026Wells FargoMaintainsOverweight—
4 May 2026CitizensMaintainsMarket Outperform—
4 May 2026GuggenheimMaintainsBuy—
4 May 2026HC Wainwright & Co.UpgradeBuy—
4 May 2026NeedhamMaintainsBuy—
27 Apr 2026CitizensInitiatesMarket Outperform—
26 Mar 2026NeedhamReiteratesBuy—
26 Mar 2026StifelMaintainsBuy—
17 Mar 2026NeedhamReiteratesBuy—
10 Mar 2026NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

CELC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Celcuity, Inc. (CELC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−22.8×

Cheaper than 96% of US stocks

Price / sales
—
Price / book
78.0×

Cheaper than 2% of US stocks

EV / EBITDA
−22.3×

Cheaper than 90% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−275.2%

Higher than 5% of US stocks

Return on assets
−37.1%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CELC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CELCCelcuity, Inc.$4.2B
28
EWTXEdgewise Therapeutics, Inc.$4.1B
52
MANEVeradermics, Inc.$4.3B
1
ACADACADIA Pharmaceuticals, Inc.$4.4B
65
RLAYRelay Therapeutics, Inc.$4.0B
94
PBLSParabilis Medicines, Inc.$4.0B
1
TNGXTango Therapeutics, Inc.$4.4B
57
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CELC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest CELC news & analysis

CELC SHAREHOLDER ALERT: Celcuity Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

Business Wire · 4 Aug 2026negative

The law firm Kirby McInerney LLP reminded investors of its investigation on behalf of Celcuity Inc. investors concerning possible violations of federal securities laws or other unlawful business practices by the company and/or members of its senior management. The alert references a July 14, 2026 press release in which Celcuity announced it had secured U.S. Food and Drug Administration approval.

Why it matters — CELC watchers would care because the firm is investigating whether the company or its senior management may have violated federal securities laws, which raises regulatory and legal risk for the company.

CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law

Business Wire · 2 Aug 2026negative

SBS Law announced that investors in Celcuity Inc. (CELC) may join a fraud investigation into the company. The announcement invites affected investors to participate in the investigation, per a Business Wire release.

Why it matters — A fraud investigation into Celcuity raises potential legal and regulatory concerns that CELC watchers would want to track.

CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm

PRNewsWire · 31 July 2026negative

A securities litigation law firm, Kessler Topaz Meltzer & Check, LLP, announced it is investigating potential federal securities law violations by Celcuity Inc. and is encouraging investors who suffered significant losses to contact the firm.

Why it matters — This investigation signals potential legal and regulatory scrutiny of Celcuity, which could impact investor confidence and the company's reputation.

Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer

GlobeNewsWire · 30 July 2026positive

The FDA-approved REVTORPYK (gedatolisib) has been included in the NCCN Clinical Practice Guidelines as a preferred Category 1 regimen for second-line or subsequent treatment of HR+/HER2- locally advanced or metastatic breast cancer in patients without a PIK3CA mutation.

Why it matters — Inclusion in NCCN guidelines is a significant endorsement that can influence clinical adoption and reimbursement for Celcuity's therapy.

NASDAQ: CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm

GlobeNewsWire · 29 July 2026negative

Kessler Topaz Meltzer & Check, LLP is investigating potential federal securities law violations by Celcuity Inc. (NASDAQ: CELC) on behalf of investors who purchased CELC securities and suffered significant financial losses.

Why it matters — CELC watchers should be aware of the securities litigation investigation, as it could lead to legal action and affect the company's reputation and stock performance.

FAQ

Frequently asked questions about CELC stock

What is the CELC stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Celcuity, Inc. have a median 12-month price target of $165, with estimates ranging from $148 to $178. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CELC stock a buy right now?

Of the 12 analysts covering Celcuity, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Celcuity, Inc. 28 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CELC?

As at 1 Aug 2026, Celcuity, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (92 of 100).

Will CELC stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +88.1% from the last close, and Ticker Nerd's factor model ranks Celcuity, Inc. 28 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CELC stock forecast for 2030?

No analyst covering Celcuity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CELC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $148 to $178 over the next 12 months.

How has CELC stock performed over the past year?

Celcuity, Inc. returned +119.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Celcuity, Inc. do?

Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications.

What is the latest news on CELC?

The most recent item we track (Business Wire, 4 Aug 2026): "CELC SHAREHOLDER ALERT: Celcuity Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations". The law firm Kirby McInerney LLP reminded investors of its investigation on behalf of Celcuity Inc. investors concerning possible violations of federal securities laws or other unlawful business practices by the company and/or members of its senior management. The alert references a July 14, 2026 press release in which Celcuity announced it had secured U.S. Food and Drug Administration approval.

Company

About Celcuity, Inc.

Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. The company’s lead product candidate, gedatolisib, is designed to inhibit the PI3K/AKT/mTOR signaling pathway, which plays a central role in cancer cell growth and survival. Celcuity’s current research and development efforts are centered on breast and prostate cancers, with additional work in other tumor types linked to the same pathway. The company also develops the CELsignia companion diagnostic platform, which analyzes live tumor cells to help identify patient groups that may benefit from targeted cancer treatments. Based in Minneapolis, Minnesota, Celcuity operates as a precision oncology company aiming to improve how cellular abnormalities are detected and addressed in cancer care.

CEO Mr. Brian F. Sullivan · 155 employees · United States · https://www.celcuity.com